Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
BioCardia Inc (BCDA)
NASDAQ:BCDA
Holding BCDA?
Track your performance easily
Earnings Data
Report Date
Apr 01, 2025TBA Not Confirmed
Period Ending
2024 (Q4)Consensus EPS Forecast
-$0.87Last Year’s EPS
-$1.35Same Quarter Last Year
Moderate Buy
Based on 1 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Nov 13, 2024
|% Change Since: -16.17%
|Next Earnings Date:Apr 01, 2025
Earnings Call Sentiment|Positive
The earnings call highlighted significant progress in clinical trials, cost reduction, and regulatory approvals, which are promising for future growth and partnerships. However, some challenges such as natural disasters impacting trial timelines and delayed revenue realization from new products were noted.Company Guidance
During the BioCardia Q3 2024 earnings call, the company provided several updates and guidance metrics. CEO Peter Altman highlighted the progress in their CardiAMP Heart Failure I and II trials, with the former involving 125 patients, 92% of whom have completed two-year follow-ups. The company anticipates releasing final results in Q1 2025, which are expected to show improved survival and reduced major adverse cardiac events. The CardiAMP Heart Failure II trial aims to enroll 250 patients and has recently expanded eligibility criteria, which could significantly boost enrollment. On the financial side, CFO David McClung reported a 41% reduction in total expenses for Q3 2024 compared to Q3 2023, with research and development expenses decreasing to $931,000. The company successfully raised $7.2 million through a public offering, ensuring compliance with NASDAQ listing requirements and extending their financial runway beyond the pivotal trial results expected in Q1 2025. Additionally, BioCardia is exploring commercialization strategies in Japan and has received FDA approval for their Morph DNA Steerable Introducer platform, with plans for commercial release.FDA Breakthrough Designation and Medicare Reimbursement
The CardiAMP cell therapy for heart failure has been granted FDA breakthrough designation and is reimbursed by Medicare, highlighting its potential impact and recognition in the medical community.
Significant Decrease in Expenses
Total expenses decreased by 41% quarter-over-quarter to $1.8 million in Q3 2024, compared to $3.0 million in Q3 2023.
Positive Enrollment and Trial Developments
The CardiAMP Heart Failure II trial has a protocol amendment approved by the FDA expected to significantly increase patient eligibility and enrollment.
Successful Public Offering
Closed a $7.2 million public offering in September, ensuring compliance with NASDAQ’s listing requirements.
FDA Approval for Morph DNA Product Family
Received FDA approval for the Morph DNA Steerable Introducer platform, covering an array of 16 products, preparing for commercial release.
---
BCDA Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
BCDA Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Nov 13, 2024 | $2.35 | $2.02 | -14.04% |
| Aug 13, 2024 | $2.64 | $2.59 | -1.89% |
| May 14, 2024 | $5.94 | $6.00 | +1.01% |
| Mar 27, 2024 | $6.29 | $6.10 | -3.02% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does BioCardia Inc (BCDA) report earnings?
BioCardia Inc (BCDA) is schdueled to report earning on Apr 01, 2025, TBA Not Confirmed.
What is BioCardia Inc (BCDA) earnings time?
BioCardia Inc (BCDA) earnings time is at Apr 01, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is BCDA EPS forecast?
BCDA EPS forecast for the fiscal quarter 2024 (Q4) is -$0.87.
---